Halozyme Therapeutics’ (HALO) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Halozyme Therapeutics (NASDAQ:HALO) in a research note released on Friday,Benzinga reports. They currently have a $90.00 price target on the biopharmaceutical company’s stock.

Several other analysts also recently weighed in on the stock. Citizens Jmp boosted their price objective on shares of Halozyme Therapeutics from $91.00 to $92.00 and gave the stock a “market outperform” rating in a research report on Tuesday, November 4th. Benchmark boosted their price target on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. Leerink Partnrs upgraded shares of Halozyme Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 14th. Citigroup reiterated a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Tuesday, November 4th. Finally, JPMorgan Chase & Co. upped their target price on Halozyme Therapeutics from $63.00 to $65.00 and gave the company a “neutral” rating in a research report on Monday, October 27th. Six equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $75.10.

Halozyme Therapeutics Trading Up 3.4%

HALO opened at $67.35 on Friday. Halozyme Therapeutics has a one year low of $46.26 and a one year high of $79.50. The company has a market cap of $7.92 billion, a P/E ratio of 14.18, a PEG ratio of 0.36 and a beta of 0.95. The company has a debt-to-equity ratio of 1.59, a quick ratio of 1.37 and a current ratio of 1.59. The business’s 50-day simple moving average is $67.14 and its 200-day simple moving average is $65.06.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.63 by $0.09. The firm had revenue of $354.26 million during the quarter, compared to analysts’ expectations of $339.18 million. Halozyme Therapeutics had a return on equity of 156.95% and a net margin of 47.91%.The firm’s revenue was up 22.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.27 earnings per share. As a group, equities research analysts expect that Halozyme Therapeutics will post 4.73 EPS for the current fiscal year.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, COO Cortney Caudill sold 4,263 shares of the stock in a transaction that occurred on Saturday, November 1st. The stock was sold at an average price of $65.19, for a total transaction of $277,904.97. Following the completion of the sale, the chief operating officer directly owned 12,737 shares of the company’s stock, valued at approximately $830,325.03. This trade represents a 25.08% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Helen Torley sold 16,569 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $68.92, for a total value of $1,141,935.48. Following the completion of the transaction, the chief executive officer owned 708,719 shares in the company, valued at $48,844,913.48. This trade represents a 2.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 85,661 shares of company stock valued at $6,036,837 in the last ninety days. Insiders own 2.90% of the company’s stock.

Hedge Funds Weigh In On Halozyme Therapeutics

Several institutional investors have recently bought and sold shares of HALO. Lindenwold Advisors INC lifted its stake in shares of Halozyme Therapeutics by 2.5% in the 3rd quarter. Lindenwold Advisors INC now owns 8,221 shares of the biopharmaceutical company’s stock worth $603,000 after acquiring an additional 201 shares during the period. Allworth Financial LP raised its holdings in Halozyme Therapeutics by 322.5% during the third quarter. Allworth Financial LP now owns 39,736 shares of the biopharmaceutical company’s stock worth $2,914,000 after purchasing an additional 30,331 shares in the last quarter. IFP Advisors Inc raised its holdings in Halozyme Therapeutics by 17.8% during the third quarter. IFP Advisors Inc now owns 5,206 shares of the biopharmaceutical company’s stock worth $382,000 after purchasing an additional 785 shares in the last quarter. Swiss Life Asset Management Ltd acquired a new stake in Halozyme Therapeutics in the third quarter valued at about $426,000. Finally, CIBC Private Wealth Group LLC boosted its holdings in Halozyme Therapeutics by 12.8% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 2,891 shares of the biopharmaceutical company’s stock valued at $212,000 after purchasing an additional 329 shares in the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.